Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

BG Medicine joins MS research center on biomarker discovery work
June 2007
SHARING OPTIONS:

WALTHAM, Mass.—BG Medicine and the Multiple Sclerosis Research Center of New York (MSRCNY) have entered into an agreement to collaborate on multiple sclerosis research. Initial projects are expected to be the discovery of biomarkers of MS disease activity and biomarkers of efficacy and safety for a currently marketed MS drug treatment.
 
  "Two hallmarks of MS are its heterogeneity—how its manifestations differ between patients—and its variability—how it can change over time through remissions and exacerbations," says Dr. Saud A. Sadiq, director of MSRCNY. "If we can supplement our clinical observations with blood tests that tell us about the level of disease activity or drug effectiveness or safety, we will advance our management of this common serious condition beyond anything imaginable at this time."

Biomarkers of disease activity can also play an important role in advancing drug discovery and development by allowing researchers to perform much smaller, shorter and lower-cost studies in comparison to studies that rely on conventional clinical observations. Additionally, MS-related biomarkers may help to better elucidate the mechanisms involved in MS susceptibility and progression.
 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.